We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.37 | 0.38% | 97.71 | 4,550 | 12:52:31 |
From May 2019 to May 2024
By Alberto Delclaux
Novartis AG (NOVN.EB) said Wednesday that its eye-care division Alcon has bought Tear Film Innovations, a company that manufactures a therapeutic device used to treat a leading cause of a condition know as dry eye.
Tear Film's iLux device, for the treatment of meibomian gland dysfunction, received 510(k) clearance from the U.S. Food and Drug Administration in December 2017 and was officially launched in May 2018, Novartis said.
"With the acquisition of Tear Film, we're excited to bring this latest innovation to treat the millions of people around the world who suffer from dry eye," said Andy Pawson, president of Alcon's global vision care franchise.
Write to Alberto Delclaux at alberto.delclaux@dowjones.com
(END) Dow Jones Newswires
December 19, 2018 01:48 ET (06:48 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
